Atopic dermatitis (AD) — the most common inflammatory skin disease — has undergone a therapeutic revolution since 2017. The approval of dupilumab (Dupixent) targeting IL-4/IL-13 signaling opened the biologic era of AD treatment, followed by an expanding pipeline of targeted therapies that have dramatically improved outcomes for moderate-to-severe disease that previously had no treatment beyond systemic immunosuppression with its significant adverse effects. For the majority of patients with mild-to-moderate AD, however, evidence-based topical management and skin barrier repair remain the foundation of care. Our skin care catalog includes medical-grade moisturizers, barrier creams, and skin care supplies used in both clinical AD management and patient self-care.
Pathophysiology: The Skin Barrier-Immune Axis
AD is fundamentally a disease of skin barrier dysfunction — loss-of-function mutations in filaggrin (FLG), a structural protein critical for stratum corneum integrity, are present in 25–30% of AD patients and are the highest genetic risk factor. Compromised barrier function allows allergen and irritant penetration, triggering Th2-biased immune responses that drive the characteristic IgE sensitization, cytokine-mediated itch, and chronic skin inflammation. This dual pathophysiology — structural barrier failure plus immune dysregulation — explains why effective treatment requires addressing both: barrier repair (emollients) plus immune modulation (topical or systemic anti-inflammatory therapy).
Emollient Therapy: The Non-Negotiable Foundation
Twice-daily application of rich emollients to the entire body surface (not just affected areas) reduces AD flare frequency, reduces topical corticosteroid use, and in high-risk infants may reduce AD development. Emollient selection matters: products containing ceramides (CeraVe, Vanicream, EpiCeram), niacinamide, or petrolatum-based formulations outperform basic lotions for skin barrier restoration in comparative studies. "Wet wrap therapy" — applying emollient under wet bandages for 15–30 minutes — provides rapid flare control and is appropriate for supervised use in moderate-to-severe acute flares. Medical-grade emollients and barrier repair creams are available in our skin care section.
Topical Pharmacotherapy
Topical corticosteroids (TCS) remain the first-line anti-inflammatory treatment for AD flares — their efficacy, rapid onset, and accessibility make them the global standard. Steroid potency selection (Class I–VII, from superpotent to low potency) depends on location (face/intertriginous: low potency only; body: moderate; palms/soles: potent). Topical calcineurin inhibitors (tacrolimus 0.03%/0.1%, pimecrolimus 1%) are steroid-sparing alternatives with no skin atrophy risk — particularly valuable for face, eyelids, and genital areas. Crisaborole (Eucrisa, PDE4 inhibitor) and ruxolitinib cream (Opzelura, JAK1/2 inhibitor) provide steroid-free alternatives for mild-to-moderate AD with distinct mechanisms.
Systemic Biologics and Small Molecules: The Modern Arsenal
Dupilumab (Dupixent, IL-4Rα antibody blocking IL-4 and IL-13 signaling) achieved >50% EASI score reduction in 75% of patients in Phase 3 trials — transforming severe AD management. Tralokinumab (Adbry, IL-13 specific), lebrikizumab (Ebglyss), and nemolizumab (IL-31 targeting pruritus) provide additional biologic options for dupilumab non-responders. JAK inhibitors (abrocitinib, upadacitinib — oral agents) achieve faster onset than dupilumab and may be preferred for patients requiring rapid flare control, though require monitoring for thromboembolic and hematologic risks and carry FDA black box warnings.
